A Phase II study of neoadjuvant combination chemotherapy with TS-1, cisplatin and Paclitaxel (PCS) for resectable advanced gastric cancer.
Phase 2
- Conditions
- resectable advanced gastric cancer
- Registration Number
- JPRN-UMIN000006674
- Lead Sponsor
- Kinki University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) With severe allergy to TS-1, Cisplatin and Paclitaxel 2) Women who are pregnant or breastfeeding. 3) Men who are unwilling to avoid pregnancy. 4) Active infection and inflammation. 5) History of cardiac disease 6) Dyspnea at rest
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method pathological complete response rate recurrence-free survival time progression-free survival overall survival proportion of transit surgery proportion of R0 resection Accomplishment rate down stage rate frequency and grade of adverse postoperative complication frequency and grade of adverse event